Beyond PDL1: OBT has recently discovered a novel T cell modulatory axis, OX001R/L, which is involved in cancer immune escape independent of the PD1/PDL1 axis. "

PRESS RELEASES

2018

Date	Title	Details
21 Dec 2018	Oxford BioTherapeutics Receives US FDA IND Clearance for OBT076: An Experimental First in Class ADC Medicine for High Risk Her2 Negative Breast Cancer, Gastric, Lung, Bladder and Ovarian Cancer Patients - US Phase I Clinical Trial to be Initiated	View here
11 Dec 2018	Oxford BioTherapeutics Expands Strategic Collaboration with  WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million	View here
01 Mar 2018	​Oxford BioTherapeutics Appoints Chief Medical Officer, ​Abderrahim Fandi	View here

2017

Date	Title	Details
12 Sept 2017	Oncology Alliance between Menarini & Oxford BioTherapeutics Progresses Second Candidate MEN1309 into the Clinic, an Antibody Drug Conjugate for the Treatment of Solid Tumors and NHL​​​​	View here
13 Jun 2017	​Oxford BioTherapeutics Appoints Senior Clinical Biotech Executive as Non-Executive Director	View here
09 Feb 2017	Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans​​​​	View here
26 Jan 2017	Oxford Finance Provides $10 Million Senior Debt Facility to Oxford BioTherapeutics​​	View here

2016

Date	Title	Details
18 Apr 2016	Boehringer Ingelheim Exercises Option on Second Oncology Target using Oxford BioTherapeutics’ OGAP® System​	View here
04 Apr 2016	Oxford BioTherapeutics Licenses Nerviano Medical Sciences’ Drug-Linker Technology to Develop Novel Antibody Drug Conjugates	View here

2015

Date	Title	Details
08 Oct 2015	Oxford BioTherapeutics Appoints Shawn Tomasello to its Board of Directors	View here
30 Jul 2015	Oxford BioTherapeutics Receives $10 Million Capital Term Loan from Silicon Valley Bank​​	View here
23 Feb 2015	Oxford BioTherapeutics to Present at 35th Cowen and Company Annual Health Care Conference in Boston​​​	View here
14 Jan 2015	Oxford BioTherapeutics Grants an Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to an Oncology Target​​​​​​	View here

2014

Date	Title	Details
25 Nov 2014	$1 Billion Oncology Alliance between Menarini Group & Oxford BioTherapeutics initiates First-in-Human Study of Enhanced Antibody for Treatment of Acute Myeloid Leukaemia	View here​​
02 Oct 2014	Oxford BioTherapeutics and Berlin-Chemie/Menarini Group Progress Antibody-Drug Conjugate as Second Clinical Development Candidate in $1 Billion Oncology Investment Alliance​	View here
07 May 2014	Oxford BioTherapeutics Takes Exclusive Rights to Use Amgen Xenomouse® Antibodies and ImmunoGen Technology to Develop Novel Antibody-Drug Conjugate for HER2-Negative Breast Cancer​	View here

2001 - 2013

Date	Title	Details
09 Dec 2013	Oxford BioTherapeutics and Menarini Progress Enhanced Antibody for Acute Myeloid Leukemia as First Clinical Development Candidate in $1 Billion Oncology Investment Alliance	View here
29 Apr 2013	Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer	View here
29 Oct 2012	Menarini Group and Oxford BioTherapeutics Collaborate for Development and Manufacture of Novel Antibody-based cancer Drugs	View here
13 Sept 2011	Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer	View here
07 Sept 2011	CMC Biologics Licenses its CHEF1® Expression System to Oxford BioTherapeutics	View here
02 Sept 2011	Oxford BioTherapeutics Licenses Lonza′s GS Gene Expression System™	View here
06 Apr 2011	Oxford BioTherapeutics Licenses BioWa′s POTELLIGENT® Technology for the Research and of its Therapeutic Antibodies in Cancer	View here
25 Jan 2011	Oxford BioTherapeutics Out-Licenses Therapeutic Antibody for the Treatment of Solid Cancers	View here​
2001-2010	News Archives ​​	View here

EVENTS CALENDAR